SCHEMBL4926263

SCHEMBL4926263

CCC(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.65
KMT2A Q03164 5/20 0.65
MAPT P10636 4/20 0.65
CASP3 P42574 1/20 0.65
TRPV1 Q8NER1 1/20 0.65
SENP7 Q9BQF6 1/20 0.65
RAB9A P51151 6/20 0.63
NPC1 O15118 5/20 0.63
HTT P42858 4/20 0.63
MAPK1 P28482 2/20 0.63
SMN1; SMN2 Q16637 3/20 0.56
XBP1 P17861 1/20 0.56
TAAR1 Q96RJ0 1/20 0.54
ALDH1A1 P00352 1/20 0.54
EPHX2 P34913 2/20 0.52
TP53 P04637 1/20 0.51
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113546 0.89 MAPT (0.52) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL4922964 0.87 MEN1 (0.61) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL655375 0.85 HTR7 (0.64) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL4112742 0.84 ALDH1A1 (0.62) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL4121515 0.83 RAB9A (0.63) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL4121462 0.82 MEN1 (0.50) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL4115524 0.82 NPC1 (0.56) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL3070329 0.81 KMT2A (0.76) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL4106292 0.80 ALDH1A1 (0.71) MEN1KMT2AMAPTCASP3TRPV1
SCHEMBL6932000 0.80 TP53 (0.60) MEN1KMT2AMAPTCASP3TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MEN1 4843/4885KMT2A 1905/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MEN1 4843/4885KMT2A 1905/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.